Fusion’s latest trading update highlights a continued financial recovery, with unaudited sales rising 11% to £838k compared to £755k in H2 2025, though still 31% lower than the same period last year (H1 2024: £1.2m). Gross margin improved to 30%, compared with H2 2025 at 5%. The company closed the period with £251k in cash and expects stronger performance in the second half, supported by a robust order book and a promising pipeline. Preparations are underway for the full launch of its flagship O ....

20 Oct 2025
Fusion Antibodies plc - Revenue up 11% in H1 2026 trading update

Sign up to access
Get access to our full offering from over 100 providers
Get access to our full offering from over 100 providers
Fusion Antibodies plc - Revenue up 11% in H1 2026 trading update
Fusion Antibodies Plc (FAB:LON) | 14.5 0 0.0% | Mkt Cap: 16.5m
- Published:
20 Oct 2025 -
Author:
Gregoire Pave -
Pages:
6 -
Fusion’s latest trading update highlights a continued financial recovery, with unaudited sales rising 11% to £838k compared to £755k in H2 2025, though still 31% lower than the same period last year (H1 2024: £1.2m). Gross margin improved to 30%, compared with H2 2025 at 5%. The company closed the period with £251k in cash and expects stronger performance in the second half, supported by a robust order book and a promising pipeline. Preparations are underway for the full launch of its flagship O ....